Cerebral sinus venous thrombosis during childhood acute lymphoblastic leukemia therapy: Risk factors and management
- 29 June 2017
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 64 (12)
Abstract
Background: Cerebral sinus venous thrombosis (CSVT) is a rare but serious complication of childhood acute lymphoblastic leukemia (ALL) therapy. No available consensus exists regarding its risk factors and appropriate management due to the rarity of cases.Procedures: Out of 209 ALL patients aged 1–21 years treated at the Children's Cancer Center of Lebanon between May 2002 and May 2015, 13 developed CSVT during therapy. Patient characteristics, clinical management, and outcomes were studied.Results: The incidence of CSVT was 6.2% (95% confidence interval [CI]: 3.4–10.4). Using univariate analysis, increased risk of CSVT was observed with age >10 years (odds ratio [OR]: 3.56, 95% CI: 1.13–11.2), T‐cell immunophenotype (OR: 4.14, 95% CI: 1.16–14.7), and intermediate/high risk disease (OR: 3.4, 95% CI: 1.03–11.7). The only statistically significant risk factor by multivariate analysis was the treatment as per the intermediate‐/high‐risk protocol (HR: 15.6, 95% CI: 1.43–171.3). Most cases (77%) occurred in the postinduction phases of treatment while receiving a combination of asparaginase and dexamethasone rather than prednisone. Treatment with low molecular weight heparin (LMWH) for a minimum of 3 months and until significant radiological improvement is observed resulted in 100% survival rate. All but one patient had complete neurological recovery.Conclusions: CSVT is an important complication of childhood ALL therapy. Postinduction combined asparaginase and dexamethasone intensive treatment for intermediate‐/high‐risk patients was the most important risk factor. Treatment with LMWH for a minimum of 3 months, and until asparginase therapy is over, with major radiological improvement seems to be effective and feasible.Keywords
This publication has 20 references indexed in Scilit:
- Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia – a multicentre study from the Nordic Society of Paediatric Haematology and OncologyBritish Journal of Haematology, 2014
- Factor V-Leiden Mutation: A Common Risk Factor for Venous Thrombosis among Lebanese PatientsThrombosis, 2012
- Implementation of an intensive risk‐stratified treatment protocol for children and adolescents with acute lymphoblastic leukemia in LebanonAmerican Journal of Hematology, 2012
- Thrombosis in Children with Acute Lymphoblastic Leukemia Treated at a Tertiary Care Center in Lebanon: Revisiting the Role of Predictive ModelsPediatric Hematology and Oncology, 2011
- Factor V Leiden thrombophiliaGenetics in Medicine, 2011
- Treating Childhood Acute Lymphoblastic Leukemia without Cranial IrradiationNew England Journal of Medicine, 2009
- Asparaginase May Influence Dexamethasone Pharmacokinetics in Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2008
- Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patientsBlood, 2006
- Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administrationBlood, 2003
- Prevalence of Two Thrombophilia Predisposing Mutations: Factor V G1691A (R506Q; Leiden) and Prothrombin G20210A, among Healthy LebaneseThrombosis and Haemostasis, 2002